Marinus Pharmaceuticals Inc. (Nasdaq: MRNS) reported positive preliminary results from an ongoing Phase 2 open-label study of ganaxolone to treat the severe, rare genetic disorder CDKL5. The stock price rose 21 cents to close at $1.37.
Marinus Pharmaceuticals reports positive study results
January 23, 2017 at 18:09 PM EST
